< Back to Press Release

December 12, 2012

Genervon established that it's targeted drug benefits ALS disorder through 8 pathways and modulates over 30 specific ALS genes dynamically

Pasadena, USA, December 12, 2012 - Genervon scientists have confirmed that the target of GM604 regulates over 4,000 genes. More significantly, it modifies ALS progression by modulating at least 30 significant ALS related genes. It does this through at least 8 pathways, potentially more, and up to 22 biological processes. These impressive and broad effects are totally consistent with the role of a master regulator of motor neurons in development. They also offer tremendous potential for broader benefits in fighting ALS and tackling its many disease alterations.

The 8 pathways are as follows: 1. Insulin receptor binding which has important therapeutic effects for ALS sufferers. 2. Mitigate mitochondrial dysfunction to reduce motoneuron death in ALS. 3. PIP3 Kinase Activation that fosters neuroprotection against ALS. 4. Bax inhibition that reduces neuron death caused by ALS. 5. Akt activation to suppress SOD1 expression that leads to ALS disorders. 6. Hypoxic response normalization that helps to prevent ALS degeneration. 7. An increase in DNA repairs capability to counter ALS neuron apoptosis. 8. Axonal transport stimulation to delay the onset of ALS.

GM604 also proved to be quite effective in the disease modification of ALS in ALS animals with mutant SOD1. It led to an improved clinical score in SOD1 mice (p<0.001 for all groups compared to control). Moreover, GM604 delayed the onset of ALS symptoms by 27%, extended life by 30% and delayed the median clinical score deterioration time in ALS mice by 41%.

GM604 also provided neuroprotection against soluble inflammatory factors from ALS human patients' Cerebral Spinal Fluid (CSF) in vitro by 175%.

GM604 dramatically increased the survival life span by 500% (6 fold from 7-14 weeks to 55-65 weeks) and increased of preservation of motor neurons by 160% (2.6 fold) in a Wobbler Mice Model for motoneuron diseases such as ALS.

Genervon has discovered a novel endogenous embryonic stage family of 9 human Master Regulators of the Nervous System. It has obtained 33 Composition of Matters and Use patents. The company has developed one of the Master Regulator named GM600 for disease modification in neurodegenerative diseases and for neuroprotection. A GM600 serial number is assigned to each indication. GM602 and GM608 are assigned to ischemic stroke and Parkinson's disease respectively which are in Phase 2 Clinical Trials. GM604 is assigned to ALS indication.

The design of optimal therapeutics by discovery of endogenous embryonic stage human master regulators is changing from hitting single pathways to a more comprehensive and dynamic approach addressing the complexity of neuro-degenerative disease. Genervon has a family of highly specific drug candidates that addresses this complexity, and believes it is at the forefront of a shift that is only beginning to be appreciated.

Genervon Biopharmaceuticals, LLC (www.genervon.com) is an innovative clinical stage biopharmaceutical company providing breakthrough biological drugs for some of the world's critical but as yet unmet medical needs.

Genervon Biopharamceuticals LLC
Dorothy Ko
1055 E. Colorado Blvd. Suite 500
Pasadena, CA 91106
Tel: (323)-721-5500



Copyright © 2017 Genervon Biopharmaceuticals, LLC. All rights reserved. All other trademarks or trade names are the property of their respective holders.